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Kui-Kai Lau1,2, Yuen-Kwun Wong1, Yap-Hang Chan3, Kai-Hang Yiu2,4, Kay-Cheong Teo1, Leonard Sheung-Wai Li5,
Shu-Leong Ho1,2, Koon-Ho Chan1,2, Chung-Wah Siu2,4 and Hung-Fat Tse2,4*Abstract
Background: Type 2 diabetes mellitus (T2DM) patients are at increased risk of developing cardiovascular events.
Unfortunately traditional risk assessment scores, including the Framingham Risk Score (FRS), have only modest
accuracy in cardiovascular risk prediction in these patients.
Methods: We sought to determine the prognostic values of different non-invasive markers of atherosclerosis,
including brachial artery endothelial function, carotid artery atheroma burden, ankle-brachial index, arterial stiffness
and computed tomography coronary artery calcium score (CACS) in 151 T2DM Chinese patients that were
identified low-intermediate risk from the FRS recalibrated for Chinese (<20% risk in 10 years). Patients were
prospectively followed-up and presence of atherosclerotic events documented for a mean duration of
61 ± 16 months.
Results: A total of 17 atherosclerotic events in 16 patients (11%) occurred during the follow-up period. The mean
FRS of the study population was 5.0 ± 4.6% and area under curve (AUC) from receiver operating characteristic curve
analysis for prediction of atherosclerotic events was 0.59 ± 0.07 (P = 0.21). Among different vascular assessments,
CACS > 40 had the best prognostic value (AUC 0.81 ± 0.06, P < 0.01) and offered significantly better accuracy in
prediction compared with FRS (P = 0.038 for AUC comparisons). Combination of FRS with CACS or other surrogate
vascular markers did not further improve the prognostic values over CACS alone. Multivariate Cox regression
analysis identified CACS > 40 as an independent predictor of atherosclerotic events in T2DM patients (Hazards Ratio
27.11, 95% Confidence Interval 3.36-218.81, P = 0.002).
Conclusions: In T2DM patients identified as low-intermediate risk by the FRS, a raised CACS > 40 was an
independent predictor for atherosclerotic events.
Keywords: Vascular markers of atherosclerosis, Type 2 diabetes mellitusBackground
Patients with type 2 diabetes mellitus (T2DM) are at
increased risk of developing adverse atherosclerotic
events including acute coronary syndrome (ACS) and is-
chemic stroke [1-3]. Various risk assessment algorithms,
for example the Framingham Risk Score (FRS) and Sys-
tematic Coronary Risk Evaluation (SCORE), aim to* Correspondence: hftse@hku.hk
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reproduction in any medium, provided the orpredict the likelihood of developing cardiovascular
events [4-6]. Some of these scores have also been recali-
brated based on the ethnic differences in cardiovascular
risk profile and incidences of cardiovascular diseases
(CVD). Nonetheless only the Framingham Risk Score
has been calibrated for use in the Chinese population
[7]. Although these algorithms are considered a useful
tool for risk stratification in the general population, they
do not have sufficient power and lack accuracy in
patients with T2DM [8-10]. Furthermore, whilst current
guidelines provide clear recommendations on initiating
anti-platelet therapy for primary prevention of CVD in. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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at low risk, there are no recommendations for those
categorized as intermediate risk [11].
Surrogate markers of atherosclerosis, including bra-
chial artery flow-mediated dilatation (FMD), carotid ar-
tery atheroma burden, ankle-brachial index (ABI),
arterial stiffness and computed tomography coronary ar-
tery calcium score (CACS) have been increasingly used
for the prediction of cardiovascular events [12-16]. Prior
studies have demonstrated that such markers improve
risk stratification of CVD in the general population
when used in conjunction with the FRS [12,14,15,17-22].
Recent studies also support the use of carotid intima-
media thickness (IMT) and CACS in conjunction with
traditional risk scores to improve risk stratification in
diabetics asymptomatic for CVD [16,23]. The prognostic
values of surrogate markers of atherosclerosis in T2DM
patients deemed low-intermediate risk is nevertheless
currently unknown. The purpose of this prospective
study was to compare the prognostic values of the FRS
with a range of commonly used surrogate markers of
atherosclerosis, used alone and in combination with the




Consecutive Chinese patients with T2DM as defined by
the WHO criteria were prospectively recruited from the
Medical Outpatient Clinics from July 2005 to December
2006 [24,25]. Patients calculated to be at high risk
(≥20%) of developing a cardiovascular event within
10 years based on the recalibrated FRS for Chinese were
excluded [7]. Patients with a history of prior athero-
thrombotic events (including ACS, ischemic stroke,
acute limb ischemia), stable angina, symptomatic periph-
eral vascular disease, creatinine level >220 μmol/L, se-
vere hepatic disease, malignancy or connective tissue
diseases were also excluded. A total of 151 patients with
T2DM were thus eligible for this study. We obtained ap-
proval from the local institutional review board and all
subjects gave written informed consent.
Study design
Baseline demographic data, cardiovascular risk factors and
cardiovascular medication at the time of recruitment were
documented. Cardiovascular risk factors including tobacco
smoking, hypercholesterolemia, hypertension and family
history of CVD diagnosed in first-degree relatives before
55 years of age were assessed. Hypertension was defined
as either resting systolic or diastolic blood pressure ≥140
or ≥90 mmHg respectively, recorded at two different clin-
ical visits or the prescription of anti-hypertensive medica-
tion [26]. Hypercholesterolemia was defined as fastingtotal plasma cholesterol ≥5.1 mmol/L or the prescription
of lipid-lowering medication [27]. Smoking status was
recorded as ever-smoker (past or current) or non-smoker.
Anthropometric measurements including body weight,
height and waist-hip circumference ratio (WHR) were
performed. Body-mass index (BMI) was calculated as
kg/m2. Systolic and diastolic blood pressures were mea-
sured and fasting blood samples were obtained to meas-
ure serum levels of glucose, hemoglobin A1c (HbA1c),
total cholesterol, triglyceride, low-density lipoprotein-
cholesterol (LDL-C), high-density lipoprotein-cholesterol
(HDL-C) and creatinine. Glomerular filtration rate
(GFR) was calculated using the Modification of Diet in
Renal Disease Study equation [28].
Vascular assessments
Vascular ultrasound examination for brachial endothelial
function, carotid IMT and presence of carotid plaque
was evaluated through a standard B-mode ultrasound
examination with the use of a 7.5 MHz linear array
transducer and a high resolution ultrasound system
(Agilent Sonos 5500, Philips, Andover, Massachusetts,
USA) as described previously [18]. Measurements of
ABI and arterial stiffness were performed using a com-
mercially available device based on the oscillometric
method (VP-2000, Colin Corporation, Komaki, Japan)
[25]. Arterial stiffness was represented by brachial to
ankle pulse wave velocity (baPWV). This method has
previously been validated and closely correlates with aor-
tic PWV [29].
A single experienced operator blinded to the status of
the study subjects performed all vascular ultrasound
examinations. Another experienced operator, also
blinded to the status of study subjects, operated on VP-
2000 and obtained ABI and arterial stiffness parameters.
Brachial endothelial function
Patients were studied in the fasting state and vasoactive
medications were withheld for 12 hours prior to the
scans. Longitudinal brachial artery diameter was
obtained at rest, and then during FMD, induced by infla-
tion of a pneumatic tourniquet placed around the fore-
arm to a pressure of 50 mmHg above systolic blood
pressure for 5 minutes. The cuff was then released and
serial imaging of the brachial artery was recorded for
5 minutes. FMD was defined as the percentage change
in brachial artery diameter between 1 minute following
cuff deflation and that on the baseline scan. All digital
images were stored on optical diskettes for subsequent
off-line analysis using a computer workstation (Echo-
PAC, GE Medical, Wisconsin, USA). A single operator
measured the brachial artery diameter and an average
value from three consecutive measurements was calcu-
lated. The intra-observer correlation coefficient for FMD
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chosen subjects).Carotid intima-media thickness and plaque
Carotid IMT was determined by measuring manually
the distance between the lumen-intima and media-
adventia border of the vascular wall using electronic
calipers. Each ultrasonic scan was performed in the an-
terior, lateral and posterior projections of the right and
left carotid arteries. Three IMT measurements were
made on the near and far wall of the common carotid
arteries, carotid bifurcation and internal carotid arteries.
The mean maximum IMT (mmIMT) was used for ana-
lysis and was calculated by averaging the values of max-
imum IMT from 12 pre-selected segments of the carotid
arteries. Presence of carotid plaque was defined as an
endoluminal protrusion of the arterial lumen of at least
0.5 mm or 50% of the surrounding IMT value or demon-
stration of an IMT of >1.5 mm [30]. The intra-observer
correlation coefficient for mmIMT was 0.97 (2 repeated
measurements in 20 randomly chosen subjects).Ankle-brachial index and arterial stiffness
Measurements of ABI and arterial stiffness were per-
formed with subjects in the supine resting position in a
quiet and temperature-controlled room. Pneumatic
pressure cuffs with oscillometric pressure sensors were
wrapped tightly around both arms and both ankles.
Electrocardiographic electrodes were attached to both
wrists and a phonocardiogram was placed at the left
second intercostal space, at the margin of the sternum.
After ensuring that patients had rested for 15 minutes,
fully automatic data acquisition began. Pressure wave-
forms of the brachial and posterior tibial arteries were
recorded. Based on the height of the patient, the device
estimated the path lengths from the brachial artery to
the posterior tibial artery. BaPWV was calculated as the
path length divided by the corresponding time interval
(cm/s). The right and left baPWV were averaged and
the resulting value selected as the representative
baPWV.
The pneumatic cuffs over both arms and ankles
enabled simultaneous measurement of systolic blood
pressure at each limb. The right-and left-sided ABI were
calculated as the ankle systolic blood pressure divided by
the brachial systolic blood pressure measured from the
right and left side, respectively. The right and left ABI
were averaged and the resulting value selected as the
representative ABI.
The intra-observer correlation coefficient for ABI was
0.85 and the intra-observer correlation coefficient for
baPWV was 0.98 (2 repeated measurements in 20 ran-
domly chosen subjects).Computed tomography coronary artery calcium score
All subjects underwent computed tomography imaging
of the coronary arteries using a 64 slice MDCT (Light-
speed, VCT, GE Healthcare, USA) as described previ-
ously [18,31]. All scans were performed with subjects in
the supine position, and included regions from the arch
of the aorta to the fundus of the heart. Prospective
electrocardiogram-gated cardiac scan was obtained with
the following scan variables: rotation time = 0.35 s, slice
thickness = 2.5 mm; 120 kV; 250 mA; trigger delay = 70%
R-R interval. Patients were instructed to breath hold for
30s during scanning.
The acquired MDCT images were reviewed at the post-
processing image workstation (Advantage windows 4.02,
GE Healthcare). Complete data were available from all
scans, with no mis-registration of slices due to artifacts of
motion, respiration, or asynchronous electrocardiographic
triggering. To ensure continuity and consistency of inter-
pretation of calcium scores, two expert investigators, who
were unaware of subject’s clinical status, analyzed all
scans. The inter-observer and intra-observer variability
correlation coefficients of CACS measurements were 0.92
and 0.91, respectively.
Measurement of CACS was performed using a com-
mercially available software “smart score” (GE Health-
care) using the threshold option set for pixels >130
Hounsefiled units and expressed in Agaston units. CACS
was calculated as the sum of calcium scores in the left
main coronary artery, left anterior descending artery, left
circumflex coronary artery, right coronary artery, and
posterior descending artery.
Clinical outcome
All patients were followed-up in our clinic every 3–
4 months. Clinical data of all patients were retrieved from
the medical records and subsequently during the most re-
cent clinic visit. An adverse atherosclerotic event was
defined as ACS, ischemic stroke, new onset symptomatic
peripheral vascular disease, death due to ACS or ischemic
stroke or symptom driven revascularization procedures of
the carotid, coronary or peripheral arteries.
Statistical analysis
Power calculation was performed based on the predic-
tion values of coronary artery calcium score for athero-
sclerotic events in patients with type 2 diabetes. Using
an alpha of 0.05 and total sample size of 151 would give
a power of 80%.
Data were expressed as mean ± standard deviation for
continuous variables and proportions for categorical vari-
ables. Baseline characteristics were compared between
groups using Student’s t-test or Chi-squared test, as ap-
propriate. Pearson’s correlation was used to measure the
correlations between vascular assessment variables. Area
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and the cut-off values of the vascular assessments with
optimal sensitivity and specificity were obtained. These
cut-off values were then used in subsequent analysis to
determine the prognostic role of these surrogate markers
in the prediction of atherosclerotic events. Chi-squared
test was also used to compare the predictive accuracy be-
tween FRS and vascular markers in atherosclerotic event
prediction. The associations between vascular assessment
parameters, categorized by AUC cut-off values, and
event-free survival were evaluated using Cox regression
models with adjustment for potential confounding vari-
ables. Only parameters with P< 0.1 in uni-variate analysis
were entered into a multi-variate model to identify the
independent predictors for atherosclerotic events. Cumu-
lative event rates were estimated using the Kaplan-Meier
method and compared using log-rank test.
All statistical analyses were performed using the statis-
tical software SPSS for Windows (Version 15.0, SPSS,
Chicago, USA) and STATA for Windows (Version 11.2,




Clinical characteristics of the study population are sum-
marized in Table 1. Their average age was 60.9 ± 10.0 years
and 40% were men. Their mean duration of DM was
15.2± 7.5 years, 60% patients had hypertension, 56% had
hypercholesterolemia, 18% were ever-smokers and 17%
had a family history of CVD. The mean HbA1C was
7.7 ± 1.2%, 16% of patients had retinopathy and the aver-
age GFR was 84 ± 22 ml/min/1.73 m2. The mean FRS of
the study population was 5.0 ± 4.6%. Results of the vascu-
lar assessment parameters are shown in Table 1.
Relationship between Framingham risk score and vascular
assessment parameters
Table 2 shows the correlation coefficients between FRS
and various vascular assessments. There was a modest
but significant correlation between FRS and mmIMT,
baPWV and CACS (all P< 0.01). CACS also correlated
well with mmIMT, ABI and baPWV (all P< 0.05) and
mmIMT correlated well with CACS, ABI and baPWV
(all P< 0.01). FMD showed no correlation with the FRS
nor with the other vascular markers.
Clinical outcomes
During a mean follow-up of 61 ± 16 months (range 3–
75 months), 17 atherosclerotic events including 1 cardio-
vascular death, 1 ACS, three ischemic stroke, 2 new
onset peripheral vascular disease and 11 percutaneous
coronary interventions were observed in 16 patients
(11% of the study population). Elective percutaneouscoronary interventions were performed at a mean of
8 ± 4 months following CT examination. All percutan-
eous coronary interventions were performed for treat-
ment of symptomatic coronary artery disease and / or
based on the presence of inducible ischemia detected by
functional assessment rather than the results of CACS.
Table 1 shows the clinical characteristics and vascular
marker parameters in patients with and without athero-
sclerotic event. Patients with atherosclerotic events were
more likely to be smokers (35% versus 16%, P=0.047).
There was also a trend for patients with atherosclerotic
events to be older (64.9 ± 10.1 years versus 60.4± 9.9 years,
P=0.079), have a lower BMI (23.8 ± 3.3 kg/m2 versus
25.8± 4.1 kg/m2, P=0.061) and a lower GFR (74± 27 ml/
min/1.73 m2 versus 85± 21 ml/min/1.73 m2, P=0.059).
There were nonetheless no significant differences between
the two groups in terms of gender, proportions with
hypertension or hypercholesterolemia, duration of DM,
HbA1c or use of medication.
Patients with atherosclerotic events had a significantly
greater carotid artery mmIMT (1.1 ± 0.3 mm versus
0.9 ± 0.2 mm, P= 0.047) and CACS (374 ± 341 versus
120 ± 346, P= 0.011) than those without atherosclerotic
events. No significant differences in FRS, brachial artery
FMD, prevalence of carotid plaque, ABI or baPWV were
observed between the two groups.Prognostic values of vascular assessments
ROC curves were constructed to obtain the prognostic
values and optimal cut-off values of the FRS as well as
different vascular assessment parameters (Table 3). All
of these parameters had good negative predictive values
(90-100%) but poor positive predictive values (14-57%).
The FRS had an AUC of 0.59 ± 0.07 (P= 0.21). In con-
trast, of all the vascular assessment parameters tested,
CACS >40 had the best predictive power for an athero-
sclerotic event (AUC 0.81 ± 0.06, P< 0.01) followed by
carotid artery mmIMT>1.07 mm (AUC 0.67 ± 0.07,
P= 0.02).
Uni-variate analysis identified age, male sex, BMI,
WHR, hypertension, FMD ≤1.12%, mmIMT >1.07 mm,
ABI ≤0.98 and CACS >40 as positive predictors for an
atherosclerotic event (all P< 0.1). Multi-variate Cox re-
gression analysis revealed that mean ABI ≤0.98 (Hazards
ratio (HR) 7.17, 95% CI (confidence interval) 1.63-31.52,
P= 0.009) and CACS >40 (HR 27.11, 95% CI 3.36-
218.81, P= 0.002) were independent predictors of an
atherosclerotic event (Table 4). There was also a trend
for mmIMT >1.07 mm as an independent predictor of
an atherosclerotic event (HR 2.76, 95% CI 0.90-8.46,
P= 0.077). In Kaplan-Meier analysis, a raised CACS >40
was associated with the occurrence of an atherosclerotic
event during follow-up (P< 0.0001, Figure 1).
Table 1 Clinical characteristics of the study population
Characteristic All With Atherosclerotic Event Without Atherosclerotic Event P-value
(N = 151) (N = 17) (N = 134)
Age, years 60.9 ± 10.0 64.9 ± 10.1 60.4 ± 9.9 0.079
Males, n (%) 61 (40) 10 (59) 51 (38) 0.10
Hypertension, n (%) 89 (60) 8 (47) 81 (62) 0.24
Hypercholesterolemia, n (%) 80 (56) 9 (60) 71 (55) 0.71
Ever-smokers, n (%) 27 (18) 6 (35) 21 (16) 0.047
Family history of CVD, n (%) 25 (17) 2 (12) 23 (17) 0.57
Duration of DM, years 15.2 ± 7.5 14.1 ± 7.8 15.3 ± 7.5 0.54
BMI, kg/m2 25.6 ± 4.1 23.8 ± 3.3 25.8 ± 4.1 0.061
WHR 88.5 ± 10.4 85.6 ± 8,5 88.9 ± 10.6 0.23
Systolic blood pressure, mmHg 140 ± 21 143 ± 21 139 ± 21 0.46
Diastolic blood pressure, mmHg 78± 9 76± 9 78± 9 0.49
Fasting blood glucose, mmol/L 7.5 ± 2.0 8.0 ± 2.9 7.5 ± 1.9 0.38
HbA1c, % 7.7 ± 1.2 7.7 ± 1.1 7.7 ± 1.3 0.94
Triglyceride, mmol/L 1.5 ± 1.2 1.5 ± 0.8 1.6 ± 1.2 0.77
Total cholesterol, mmol/L 4.9 ± 0.9 5.0 ± 1.1 4.9 ± 0.9 0.69
LDL-C, mmol/L 2.8 ± 0.8 3.0 ± 0.8 2.8 ± 0.7 0.46
HDL-C, mmol/L 1.4 ± 0.4 1.4 ± 0.3 1.4 ± 0.4 0.73
GFR, ml/min/1.73 m2 84 ± 22 74 ± 27 85 ± 21 0.059
Beta-blocker, n (%) 29 (21) 2 (13) 27 (22) 0.40
Calcium channel blocker, n (%) 50 (36) 4 (25) 46 (37) 0.35
ACEI/ARB, n (%) 44 (31) 6 (38) 38 (30) 0.56
Aspirin, n (%) 8 (6) 1 (6) 7 (6) 0.92
Statin, n (%) 30 (21) 5 (31) 25 (20) 0.31
Oral hypoglycemic agent, n (%) 115 (82) 13 (81) 102 (82) 0.92
Insulin, n (%) 24 (17) 2 (13) 22 (18) 0.60
Retinopathy, n (%) 23 (16) 3 (19) 20 (16) 0.76
Urine albumin g/l 0.07 ± 0.2 0.1 ± 0.3 0.1 ± 0.2 0.60
FRS, % 5.0 ± 4.6 5.9 ± 5.0 4.9 ± 4.5 0.41
FMD, % 2.8 ± 3.8 1.7 ± 3.9 2.9 ± 3.7 0.22
mmIMT, mm 0.9 ± 0.2 1.1 ± 0.3 0.9 ± 0.2 0.047
Carotid plaque, n (%) 85 (57) 12 (71) 73 (55) 0.22
ABI 1.1 ± 0.1 1.0 ± 0.2 1.1 ± 0.1 0.080
baPWV, cm/s 1752 ± 384 1897± 373 1732± 383 0.20
CACS 148± 353 374± 341 120 ± 346 0.011
Abbreviations: ABI = ankle brachial index; ACEI = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker; baPWV=brachial-ankle pulse wave
velocity; BMI = body mass index; CACS = coronary artery calcium score; CVD= cardiovascular disease; DM=diabetes mellitus; FMD= flow mediated dilatation;
FRS = Framingham Risk Score; GFR = glomerular filtration rate; HbA1c = haemoglobin A1c; HDL= high-density lipoprotein cholesterol; LDL-C = low-density
lipoprotein cholesterol; mmIMT =mean maximum intima-media thickness; WHR=waist-hip circumference ratio.
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atherosclerotic events against other vascular assessment
markers, alone and in combination with the FRS
(Table 5). CACS had significantly greater AUC compared
with FRS (AUC 0.81 versus 0.59, P= 0.038). There were
no significant differences in AUC between other vascularmarkers and FRS (all P> 0.05). Combining CACS with
FRS provided incremental benefit in risk prediction com-
pared with FRS alone (AUC 0.77 versus 0.59, P= 0.013)
but did not offer further benefit compared with CACS
alone. Combination of FRS with other vascular markers
also did not provide further incremental benefit.
Table 2 Pearson correlation coefficients between FRS and
vascular assessment parameters
FMD mmIMT ABI baPWV CACS
mmIMT −0.07
ABI 0.02 −0.42**
baPWV 0.10 0.36** −0.22
CACS 0.03 0.35** −0.29* 0.49**
FRS −0.06 0.31** −0.17 0.34** 0.33**
Abbreviations as in Table 1.
*P < 0.05, **P < 0.01.
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This study compared the diagnostic value of non-
invasive markers of atherosclerosis, used alone and with
the FRS, in the prediction of atherosclerotic events in
Chinese T2DM deemed low-intermediate risk. The
results of our study show that in Chinese T2DM patients
of low-intermediate risk, 11% developed an atheroscler-
otic event during a mean follow-up of 61 ± 16 months.
The FRS only had a modest accuracy in prediction of
atherosclerotic events in our study. In contrast, among
the different surrogate markers of atherosclerosis evalu-
ated, a raised CACS> 40 offered the best prognostic
value and was superior to FRS in risk prediction. It was
also an independent predictor of a future atherosclerotic
event. Although combination of CACS with FRS pro-
vided incremental benefit in risk prediction versus FRS
alone, such a combination did not offer further prognos-
tic value compared with CACS alone.
Limitations of traditional risk scores
The FRS has been successful in prediction of CVD in
general populations. The risk algorithm nonetheless
lacks accuracy in patients with diabetes [4,5]. Studies
using the FRS in different population groups have found
that the FRS has both under- and over-estimated CVD
risk in patients with DM [8-10]. Such an observation has
been postulated to be related to a small number of dia-
betic patients in the original Framingham cohort (4% of
5573 subjects) from which the equation was derived.Table 3 Prognostic values of FRS and vascular assessments ac
Markers AUC (SE) Cut-off values Sensitivity,
FRS 0.59 ± 0.07 >2.56 % 82.4 (56.
FMD 0.59 ± 0.08 ≤1.12 % 52.9 (27.
mmIMT 0.67 ± 0.07* >1.07 mm 41.2 (18.
Carotid plaque 0.58 ± 0.06 - 70.6 (44.
ABI 0.64 ± 0.10 ≤0.98 33.3 (9.9
baPWV 0.63 ± 0.09 >1467 cm/s 100.0 (69.
CACS 0.81 ± 0.06** >40 92.9 (66.
Abbreviations as in Table 1 and AUC= area under curve; SE = standard error; CI = co
value*P < 0.05, **P < 0.01.Glycemic control as well as duration of diabetes are also
considered important parameters in determining CVD
risk and should be included in risk algorithms [8].
Among Chinese, the FRS also overestimates cardiovas-
cular risk, leading to a recent recalibration to suit the
Chinese population [7]. Although this has led to
improved risk estimation, recent studies have further
identified limitations of such a model due to the greater
prevalence of stroke than coronary heart disease in
China [32]. In this study, the average FRS of our study
population was only 5.0 ± 4.6% for prediction of cardio-
vascular events in 10 years but up to 11% (16 out of
151) of patients developed an adverse cardiovascular
event within a mean follow-up period of 61 ± 16 months,
thus highlighting the limitations of the FRS.
Use of vascular markers in improving cardiovascular risk
stratification
In view of the FRS’s drawbacks, further strategies to im-
prove risk stratification should be implemented. Previous
studies have identified that use of non-invasive surrogate
markers of atherosclerosis including brachial artery
FMD, carotid atheroma burden, ABI, arterial stiffness
and CACS improve CVD risk stratification in the gen-
eral population [12,14,15,17-22]. Fewer such studies have
been performed in a population limited to patients with
T2DM. Recent studies have shown that combination of
the FRS with carotid artery IMT provides greater pre-
dictive power of cardiovascular events compared with
FRS alone [23,33], but such a benefit was not observed
when combining baPWV with FRS [23]. Similarly the
PREDICT study provided evidence that measurement of
the CACS was a powerful predictor of cardiovascular
events in asymptomatic patients with T2DM and was
able to improve risk prediction as calculated by the Uni-
ted Kingdom Prospective Diabetes Study risk model
[16].
Amongst commonly used non-invasive surrogate mar-
kers of atherosclerosis, a raised CACS was determined
to have the best prognostic value in this study with a
high negative predictive value of 98.7%. This finding iscording to specified cut-off values
% (95%CI) Specificity, % (95 % CI) PPV, % NPV, %
6-96.2) 47.8 (39.1-56.6) 16.7 95.5
8-77.0) 72.4 (64.0-79.8) 19.6 92.4
4-67.1) 85.7 (78.6-91.2) 26.9 91.9
0-89.7) 45.11 (36.5-54.0) 14.1 92.3
-65.1) 95.9 (88.5-99.1) 57.1 89.7
2-100.0) 26.4 (16.7-38.1) 15.9 100
1-99.8) 67.3 (57.8-75.8) 26.0 98.7
nfidence interval; PPV = positive predictive value; NPV= negative predictive
Table 4 Multivariate Cox regression for atherosclerotic events in relation to vascular markers and risk factors
Risk variable mmIMT ABI CACS
HR (95 % CI) P- value HR (95 % CI) P-value HR (95 % CI) P-value
mmIMT> 1.07 mm 2.76 (0.90-8.46) 0.077 - - - -
ABI≤ 0.98 - - 7.17 (1.63-31.52) 0.009 - -
CACS> 40 - - - - 27.11 (3.36-218.81) 0.002
Age 1.05 (1.00-1.11) 0.079 1.03 (0.97-1.09) 0.33 1.01 (0.95-1.08) 0.70
Males 2.32 (0.79-6.78) 0.12 2.43 (0.81-7.25) 0.11 2.17 (0.64-7.41) 0.22
BMI 0.91 (0.67-1.24) 0.56 0.85 (0.63-1.15) 0.29 0.81 (0.58-1.12) 0.20
WHR 1.00 (0.89-1.12) 0.99 1.02 (0.91-1.14) 0.73 1.05 (0.93-1.19) 0.41
Hypertension 0.55 (0.20-1.51) 0.24 0.71 (0.25-2.00) 0.52 0.53 (0.18-1.60) 0.26
Abbreviations as in Tables 1, 2, 3.
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to be superior to other markers for CVD prediction in
the general population [22,34]. It has been suggested
that the superiority of CACS in coronary heart disease
prediction is likely related to the direct measurement of
atheroma burden in the vasculature bed of interest [22].
Nonetheless despite a range of end points related to ath-
erosclerotic disease being used in this study, CACS
remained superior to other vascular markers. The sig-
nificant correlations of CACS with mmIMT, ABI and ar-
terial stiffness suggests that CACS is not only a
reflection of atheroma burden in the coronary arteries
but of other vasculature beds including the carotid arter-
ies and peripheral vasculatures.
The most recent international guidelines provide
clear recommendations for initiation of antiplatelet
therapy in diabetic patients considered to be at high
cardiovascular risk (men >50 years or women >60 years
with one additional major cardiovascular risk factor)
and does not recommend such therapy for those at
low risk (men <50 years or women <60 years with no
major cardiovascular risk factors) [11]. Nonetheless theFigure 1 Kaplan-Meier curve for the development of
atherosclerotic events in patients with CACS> 40 or CACS≤ 40.prescription of anti-platelet agents remains a matter of
clinical judgment for those at intermediate risk e.g.
young patients with cardiovascular risk factors or older
patients with no risk factors [11]. Our results show
that screening of atherosclerotic burden with CACS
may identify a high risk subgroup of diabetic patients
who have been classified as intermediate risk using
FRS. This group of patients may benefit from more ag-
gressive preventive measures, including lipid lowering
and anti-platelet therapy for CVD. Our results echo
those from previous studies that have also demon-
strated CACS as a powerful predictor of CVD and all-
cause mortality as well as enhancing risk prediction in
asymptomatic diabetic patients [16,26,35,36].
Limitations
In this prospective observational study, there was a small
sample size that of only 151 Chinese patients with
T2DM resulting in 17 events. Further large scale studies
replicated in other ethnic populations and using other
risk algorithms are needed to confirm our findings. In
addition, there is increasing interest in coronary artery
plaque location and morphology as detected by contrast
CT coronary angiogram but this was not assessed in the
current study [35,37]. Finally, whilst serial monitoring ofTable 5 Comparison of the AUC of FRS alone and in
combination with vascular assessment markers for
atherosclerotic events
AUC (SE) P-Value
FRS 0.59 ± 0.07 -
FRS + FMD 0.62 ± 0.07 0.66
FRS +mmIMT 0.67 ± 0.07 0.34
FRS + carotid plaque 0.61 ± 0.07 0.77
FRS +ABI 0.67 ± 0.10 0.29
FRS + baPWV 0.66 ± 0.09 0.30
FRS + CACS 0.77 ± 0.06 0.013
Abbreviations as in Tables 1, 2, 3.
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http://www.cardiab.com/content/11/1/101surrogate markers of atherosclerosis in diabetics have re-
cently been studied to delineate the change in vascular
parameters with treatment and time, this was not per-
formed in our study [36,38].
Conclusions
In this small study, detection of CACS > 40 was an inde-
pendent predictor for atherosclerotic events in T2DM
patients identified as low-intermediate risk by the FRS.
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